Drug Trial Radar · NCT00423644
A Phase II Trial of ZIO-101 in Advanced Multiple Myeloma: Protocol SGL2001b
Last checked: Nov 20, 2026Latest source record: Sep 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
17
Actual
Start
Jan 2007
Primary completion
Dec 21, 2007
Study completion Dec 21, 2008
Sponsor
- Lead sponsor
- Alaunos TherapeuticsIndustry
- Sponsor type
- Industry
- First posted
- Jan 18, 2007
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The study of safety of a new organic arsenic compound in the treatment of advanced multiple myeloma
Conditions
- Multiple Myeloma
Interventions
DarinaparsonDrug
420 mg/m2 of Darinaparsin given twice weekly for three weeks, followed by one week of rest for up to six months
Primary outcomes
What the sponsor says the trial is designed to measure.
- Response RateTime frame: 6 months
Locations
8 sites in 1 country. Site status is shown where the registry gives one.
Site not named
Glendale, Arizona
Site not named
Santa Barbara, California
Site not named
Santa Rosa, California
Site not named
West Hollywood, California
Site not named
Bethesda, Maryland
Site not named
Buffalo, New York
Site not named
Charlotte, North Carolina
Site not named
Sioux Falls, South Dakota
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.